Department of Internal Medicine, Staten Island University Hospital, 300 Constitution Avenue, Apartment 109, Bayonne, NJ 07002, USA.
Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, ML7028, Cincinnati, OH 45229, USA.
Immunol Allergy Clin North Am. 2024 Nov;44(4):615-627. doi: 10.1016/j.iac.2024.07.002. Epub 2024 Aug 26.
Eosinophilic gastrointestinal diseases (EGIDs) encompass a group of disorders characterized by an abnormal accumulation of eosinophils in various parts of the gastrointestinal tract. EGIDs present with a wide range of symptoms such as abdominal pain, vomiting, diarrhea, difficulty swallowing, and food impaction. Monoclonal antibodies, targeting inflammatory cytokines or eosinophils, are the next emerging therapy for EGIDs. The only Food and Drug Administration-approved monoclonal antibody is dupilumab, and it has been approved for the treatment of eosinophilic esophagitis (EoE). In this article, the authors will discuss biologics that have been used in the treatment of eosinophilic gastrointestinal diseases.
嗜酸性粒细胞性胃肠道疾病（EGIDs）是一组以胃肠道各部位嗜酸性粒细胞异常积聚为特征的疾病。EGIDs 的表现症状多样，包括腹痛、呕吐、腹泻、吞咽困难和食物嵌塞等。针对炎症细胞因子或嗜酸性粒细胞的单克隆抗体是 EGIDs 的新兴治疗方法。唯一获得美国食品和药物管理局批准的单克隆抗体是度普利尤单抗，它已被批准用于治疗嗜酸性食管炎（EoE）。本文作者将讨论已用于治疗嗜酸性粒细胞性胃肠道疾病的生物制剂。
